Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...

The FDA’s approval was supported by data from the PROGRESS study’s cohort 1. Credit: murat photographer/Shutterstock.com. The US Food and Drug Administration (FDA ...

Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.

Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.

The partnership brings together BoomRay’s development experience in RLTs and Novartis’s global presence in the field. Credit: Michael Derrer Fuchs / Shutterstock.com. China-based clinical-stage ...